Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 16/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 16/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 16/20 | 1.00 |
| ▸ | NISCH | Q9Y2I1 | 5/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 5/20 | 0.63 |
| ▸ | MAOB | P27338 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexlofexidine SCHEMBL124602 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CNISCHHTR1A | |
| Levlofexidine SCHEMBL947241 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CNISCHHTR1A | |
| Lofexidine SCHEMBL48960 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CNISCHHTR1A | |
| SCHEMBL9917089 | 0.83 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CNISCHHTR1A | |
| SCHEMBL19961884 | 0.83 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CNISCHHTR1A | |
| Hydrochloric Acid SCHEMBL9654915 | 0.82 | NISCH (0.77) | ADRA2AADRA2BADRA2CNISCHHTR1A | |
| Lofexidine SCHEMBL22616208 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CNISCHHTR1A | |
| Lofexidine SCHEMBL3500726 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CNISCHHTR1A | |
| Lofexidine SCHEMBL678553 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CNISCHHTR1A | |
| Lofexidine SCHEMBL124601 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CNISCHHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016105448-A1 | IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS | RIDEOUT DARRYL (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | ADRA2A 331/4885ADRA2B 201/4885ADRA2C 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.